CalciMedica is trading 8.4% up in pre-market at $0.77, after rising from the August 6 close of $0.71; no new company-specific announcement or reliable report clearly explains the August 7 pre-market move.
- Recent background includes FDA alignment on Auxora’s Phase 2b acute-pancreatitis trial design on July 29.
- An upcoming shareholder vote involves a potential reverse split, warrants, and share issuances, but neither directly explains the move.